immatics biotechnologies GmbH (4A3) — Capital Reinvestment Ratio
immatics biotechnologies GmbH (4A3) has a Capital Reinvestment Ratio of 0.12x as of December 2023, meaning it reinvests 0% of its operating cash flow (€79.08 Million) in capital expenditures (€9.29 Million). See cash generation quality of immatics biotechnologies GmbH to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
immatics biotechnologies GmbH Capital Reinvestment Ratio (2018–2023)
This chart tracks immatics biotechnologies GmbH's Capital Reinvestment Ratio across 6 annual periods.
Annual Capital Reinvestment Ratio for immatics biotechnologies GmbH (2018–2023)
Year-by-year Capital Reinvestment Ratio for immatics biotechnologies GmbH from 2018 to 2023. For live market cap and broader valuation context, see immatics biotechnologies GmbH stock valuation.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 1.70x | €18.23 Million | €30.96 Million | ▲ +2863.7% |
| 2022 | 0.06x | €100.13 Million | €5.74 Million | ▲ +12.4% |
| 2021 | 0.05x | €100.13 Million | €5.11 Million | ▼ -31.2% |
| 2020 | 0.07x | €100.13 Million | €7.42 Million | ▲ +145.4% |
| 2019 | 0.03x | €70.97 Million | €2.14 Million | ▲ +45.6% |
| 2018 | 0.02x | €20.68 Million | €429.00K | — |